Edgardo S. Santos, MD

home / authors / edgardo-s-santos-md

Articles

Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the Lung

March 15th 2023

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Prophylactic Approaches to the Management of CIM in ES-SCLC

Martin Dietrich, MD, PhD;Edgardo S. Santos, MD

July 8th 2022

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

An Overview of Chemotherapy-Induced Myelosuppression in ES-SCLC

Martin Dietrich, MD, PhD;Edgardo S. Santos, MD

July 8th 2022

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.

Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC

Edgardo S. Santos, MD

August 17th 2021

Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.

Dr. Santos on Exciting Advancements in Field of Lung Cancer

Edgardo S. Santos, MD

November 22nd 2016

Edgardo S. Santos, MD, medical oncology, internal medicine, Boca Raton Regional Hospital, discusses exciting advancements in the field of lung cancer. Santos shared this insight during the 2016 OncLive State of the Science Summit on Lung Cancer.